{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T07:28:09Z","timestamp":1793950089692,"version":"4.8.0"},"reference-count":160,"publisher":"Informa UK Limited","issue":"10","license":[{"start":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:00:00Z","timestamp":1789171200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:00:00Z","timestamp":1789171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"name":"CSIC","award":["BILAT23016"],"award-info":[{"award-number":["BILAT23016"]}]},{"name":"AEI, Spain","award":["PID2024-159248OB-I00"],"award-info":[{"award-number":["PID2024-159248OB-I00"]}]},{"name":"Instituto de Salud Carlos III CIBERNED","award":["CB18\/05\/00040"],"award-info":[{"award-number":["CB18\/05\/00040"]}],"id":[{"id":"https:\/\/ror.org\/00ca2c886","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Fundaci\u00f3n HNA","award":["FPU21\/01392"],"award-info":[{"award-number":["FPU21\/01392"]}]},{"name":"MCIU"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2026,10,3]]},"DOI":"10.1080\/13543784.2026.2729512","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:44:59Z","timestamp":1789055099000},"page":"715-733","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Innovative therapies under clinical development for ALS treatment. Part 2: biologics and natural products"],"prefix":"10.1080","volume":"35","author":[{"given":"Chi-Chen Sarah","family":"Huang","sequence":"first","affiliation":[{"name":"Taipei Medical University and National Health Research Institutes","place":["Taipei City, Taiwan"]},{"name":"Taipei Medical University","place":["New Taipei City, Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Sanchez-Santos","sequence":"additional","affiliation":[{"name":"Centro de Investigaciones Biologicas \u201cMargarita Salas\u201d-CSIC","place":["Madrid, Spain"]},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red en Enfermedades Neurodegenerativas, (CIBERNED), Instituto de Salud Carlos III, Avda","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loreto","family":"Martinez-Gonzalez","sequence":"additional","affiliation":[{"name":"Centro de Investigaciones Biologicas \u201cMargarita Salas\u201d-CSIC","place":["Madrid, Spain"]},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red en Enfermedades Neurodegenerativas, (CIBERNED), Instituto de Salud Carlos III, Avda","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Gil","sequence":"additional","affiliation":[{"name":"Centro de Investigaciones Biologicas \u201cMargarita Salas\u201d-CSIC","place":["Madrid, Spain"]},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red en Enfermedades Neurodegenerativas, (CIBERNED), Instituto de Salud Carlos III, Avda","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Martinez","sequence":"additional","affiliation":[{"name":"Centro de Investigaciones Biologicas \u201cMargarita Salas\u201d-CSIC","place":["Madrid, Spain"]},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red en Enfermedades Neurodegenerativas, (CIBERNED), Instituto de Salud Carlos III, Avda","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,9,12]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-022-00612-2"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells12111523"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cnp.2023.11.004"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000001294"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2026.1729302"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2005.032300"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-025-12975-8"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jnatprod.5c01368"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2025.0145"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70091"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116432"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.4103\/1673-5374.244783"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.28372"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-020-00114-z"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-022724-095035"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2026.2667249"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2012.225"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2023.12.003"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2003715"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2022-abn2.6"},{"key":"e_1_3_5_23_1","unstructured":"FDA [Internet]. MD: FDA; [cited 2026 May 6]. Available from: https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-treatment-amyotrophic-lateral-sclerosis-associated-mutation-sod1-gene"},{"key":"e_1_3_5_24_1","unstructured":"EMA [Internet]. Amsterdam: EMA; [cited 2026 May 6]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/qalsody"},{"key":"e_1_3_5_25_1","unstructured":"ClinicalTrials.gov [Internet]. [cited 2026 May 6]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07294144"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2025.07.045"},{"key":"e_1_3_5_27_1","unstructured":"PRNewswire [Internet]. Chicago: Biogen and Ionis; [cited 2026 May 6]. Available from: https:\/\/www.prnewswire.com\/news-releases\/biogen-and-ionis-announce-topline-phase-1-study-results-of-investigational-drug-in-c9orf72-amyotrophic-lateral-sclerosis-301511359.html"},{"key":"e_1_3_5_28_1","unstructured":"GlobeNewswire [Internet]. El Segundo: Wave Life Sciences Ltd. [cited 2026 May 6]. Available from: https:\/\/www.globenewswire.com\/news-release\/2023\/05\/23\/2674200\/0\/en\/Wave-Life-Sciences-Announces-Topline-Results-from-Phase-1b-2a-FOCUS-C9-Study-of-WVE-004-for-C9orf72-associated-Amyotrophic-Lateral-Sclerosis-and-Frontotemporal-Dementia.html"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)00513-6"},{"key":"e_1_3_5_30_1","unstructured":"ClinicalTrials.gov [Internet]. [cited 2026 May 6]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04768972"},{"key":"e_1_3_5_31_1","unstructured":"ClinicalTrials.gov [Internet]. ClinicalTrials.gov; [cited 2026 May 6]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07095712"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000205187"},{"key":"e_1_3_5_33_1","unstructured":"ENCALS [Internet]. Utrecht: ENCALS2025. [cited 2026 May 6]. Available from: https:\/\/www.quralis.com\/wp-content\/uploads\/2025\/09\/QRL-201-ENCALS-2025-ALS-Poster.pdf"},{"key":"e_1_3_5_34_1","unstructured":"ClinicalTrials.gov [Internet]. ClinicalTrials.gov; [cited 2026 May 6]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07100119"},{"key":"e_1_3_5_35_1","unstructured":"Biogen [Internet]. Cambridge: Biogen Inc; [cited 2026 May 6]. Available from: https:\/\/investors.biogen.com\/news-releases\/news-release-details\/biogen-and-ionis-announce-topline-phase-12-study-results"},{"key":"e_1_3_5_36_1","unstructured":"ClinicalTrials.gov [Internet]. ClinicalTrials.gov; [cited 2026 May 6]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07095686"},{"key":"e_1_3_5_37_1","unstructured":"Amylyx [Internet]. Cambridge: Amylyx Pharmaceuticals Inc.; [cited 2026 May 6]. Available from: https:\/\/www.amylyx.com\/news\/amylyx-pharmaceuticals-announces-new-safety-and-tolerability-cohort-1-data-of-amx0114-in-als-from-first-in-human-lumina-trial"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01346-1"},{"key":"e_1_3_5_39_1","unstructured":"SV Health Investors [Internet]. London: Leal Therapeutics Inc.; [cited 2026 May 6]. Available from: https:\/\/svhealthinvestors.com\/news\/leal-therapeutics-announces-executive-leadership-appointments-and-provides-business-update"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2024.102437"},{"key":"e_1_3_5_41_1","unstructured":"ClinicalTrials.gov [Internet]. [cited 2026 May 6]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06351592"},{"key":"e_1_3_5_42_1","unstructured":"ClinicalTrials.gov [Internet]. [cited 2026 May 6]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06556394"},{"key":"e_1_3_5_43_1","unstructured":"ClinicalTrials.gov [Internet]. [cited 2026 May 6]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05949294"},{"key":"e_1_3_5_44_1","unstructured":"ClinicalTrials.gov [Internet]. [cited 2026 May 6]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07080801"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmacy12020058"},{"key":"e_1_3_5_46_1","unstructured":"PRNewswire [Internet]. Chicago: AL-S Pharma; [cited 2026 May 6]. Available from: https:\/\/www.prnewswire.com\/news-releases\/al-s-pharma-announces-positive-topline-results-from-phase-2-study-of-ap-101-for-the-treatment-of-amyotrophic-lateral-sclerosis-als-302545686.html"},{"key":"e_1_3_5_47_1","unstructured":"Annexon [Internet]. Brisbane: Annexon Inc.; [cited 2026 May 6]. Available from: https:\/\/ir.annexonbio.com\/news-releases\/news-release-details\/annexon-highlights-strategic-focus-advance-four-flagship\/"},{"key":"e_1_3_5_48_1","unstructured":"Eledon Pharmaceuticals [Internet]. Irvine: Eledon Pharmaceuticals Inc.; [cited 2026 May 6]. Available from: https:\/\/ir.eledon.com\/news-releases\/news-release-details\/eledon-announces-positive-topline-results-phase-2a-trial"},{"key":"e_1_3_5_49_1","unstructured":"ClinicalTrials.gov [Internet]. [cited 2026 May 6]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05053035?tab=results"},{"key":"e_1_3_5_50_1","unstructured":"ClinicalTrials.gov [Internet]. [cited 2026 May 6]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06453668"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajt.2023.05.032"},{"key":"e_1_3_5_52_1","unstructured":"ClinicalTrials.gov [Internet]. [cited 2026 May 6]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07193953"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000205610"},{"key":"e_1_3_5_54_1","unstructured":"ClinicalTrials.gov [Internet]. [cited 2026 May 6]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06643481"},{"key":"e_1_3_5_55_1","unstructured":"ClinicalTrials.gov [Internet]. [cited 2026 May 6]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06441682"},{"key":"e_1_3_5_56_1","unstructured":"euclinicaltrials [Internet]. euclinicaltrials. [cited 2026 May 6]. Available from: https:\/\/euclinicaltrials.eu\/search-for-clinical-trials\/?lang=en&EUCT=2022-502743-35-00"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2010.00032"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.59058"},{"key":"e_1_3_5_59_1","unstructured":"ClinicalTrials.gov [Internet]. ClinicalTrials.gov; [cited 2026 May 6]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04579666"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.3390\/biom14060635"},{"key":"e_1_3_5_61_1","unstructured":"ClinicalTrials.gov [Internet]. ClinicalTrials.gov; [cited 2026 May 6]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06391645"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2017.188"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12987-019-0123-z"},{"key":"e_1_3_5_64_1","unstructured":"ClinicalTrials.gov [Internet]. ClinicalTrials.gov; [cited 2026 May 6]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06365216"},{"key":"e_1_3_5_65_1","unstructured":"ClinicalTrials.gov [Internet]. ClinicalTrials.gov; [cited 2026 May 6]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05978908"},{"key":"e_1_3_5_66_1","unstructured":"Harnessing stem-cell derivatives to treat CNS diseases. Biopharma Dealmakers. 2024;B18."},{"key":"e_1_3_5_67_1","unstructured":"Coya Therapeutics [Internet]. Houston: Coya Therapeutics Inc; [cited 2026 May 6]. Available from: https:\/\/ir.coyatherapeutics.com\/news\/news-details\/2025\/Coya-Therapeutics-COYA-302-ALS-Trial-Accepted-by-NEALS-as-a-NEALS-Affiliated-Trial\/default.aspx"},{"key":"e_1_3_5_68_1","unstructured":"ClinicalTrials.gov [Internet]. ClinicalTrials.gov; [cited 2026 May 6]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07161999"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2023.2178416"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainresbull.2023.01.008"},{"key":"e_1_3_5_71_1","unstructured":"International alliance of ALS\/MND Associations [Internet]. UK: Corestem Chemon; [cited 2026 May 6]. Available from: https:\/\/www.als-mnd.org\/support-for-pals-cals\/drugs-in-development\/neuronata-r\/"},{"key":"e_1_3_5_72_1","unstructured":"BrainStorm Cell Therapeutics [Internet]. NY: BrainStorm Cell Therapeutics Inc.; [cited 2026 May 6]. Available from: https:\/\/ir.brainstorm-cell.com\/2025-07-08-FDA-Review-of-Citizen-Petition-Offers-a-Fresh-Look-at-NurOwn-R-s-Evidence-of-Treatment-Effectiveness"},{"key":"e_1_3_5_73_1","unstructured":"ClinicalTrials.gov [Internet]. ClinicalTrials.gov; [cited 2026 May 6]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06973629?cond=ALS&firstPost=2025-01-12_2026-01-14&rank=28"},{"key":"e_1_3_5_74_1","unstructured":"ClinicalTrials.gov [Internet]. ClinicalTrials.gov; [cited 2026 May 6]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07118319"},{"key":"e_1_3_5_75_1","unstructured":"ClinicalTrials.gov [Internet]. ClinicalTrials.gov; [cited 2026 May 6]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06344260"},{"key":"e_1_3_5_76_1","unstructured":"ClinicalTrials.gov [Internet]. ClinicalTrials.gov; [cited 2026 May 6]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06910384"},{"key":"e_1_3_5_77_1","unstructured":"ClinicalTrials.gov [Internet]. ClinicalTrials.gov; [cited 2026 May 6]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04849065"},{"key":"e_1_3_5_78_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34526-9"},{"key":"e_1_3_5_79_1","unstructured":"ClinicalTrials.gov [Internet]. ClinicalTrials.gov; [cited 2026 May 6]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06671236"},{"key":"e_1_3_5_80_1","unstructured":"ClinicalTrials.gov [Internet]. ClinicalTrials.gov; [cited 2026 May 6]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05695521"},{"key":"e_1_3_5_81_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232415942"},{"key":"e_1_3_5_82_1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12102193"},{"key":"e_1_3_5_83_1","unstructured":"ClinicalTrials.gov [Internet]. ClinicalTrials.gov; [cited 2026 May 6]. Available from: https:\/\/clinicaltrials.gov\/search?cond=ALS%20&intr=hUC-MSC-sEV-001%20&viewType=Card"},{"key":"e_1_3_5_84_1","doi-asserted-by":"publisher","DOI":"10.62347\/FTXA8845"},{"key":"e_1_3_5_85_1","unstructured":"PRNewswire [Internet]. Chicago: Helixmith; [cited 2026 May 6]. Available from: https:\/\/www.prnewswire.com\/news-releases\/helixmith-announces-topline-results-from-phase-2a-study-of-engensis-for-treatment-of-als-amyotrophic-lateral-sclerosis-301617401.html"},{"key":"e_1_3_5_86_1","unstructured":"Neuro Central [Internet]. Oxfordshire: XaludTherapeutic; [cited 2026 May 6]. Available from: https:\/\/www.neuro-central.com\/xalud-therapeutics-lead-candidate-xt-150-achieves-multiple-clinical-milestones-in-pathologic-inflammation-and-neuroimmunology-therapeutic-areas\/"},{"issue":"75","key":"e_1_3_5_87_1","article-title":"Efficacy of XT-150, a novel non-viral gene therapy delivering IL-10v, on moderate to severe pain due to osteoarthritis of the knee: results of a phase 2 trial","author":"Grigsby E","year":"2023","unstructured":"Grigsby E, Collins S, Kapural L, et al. Efficacy of XT-150, a novel non-viral gene therapy delivering IL-10v, on moderate to severe pain due to osteoarthritis of the knee: results of a phase 2 trial. Arthritis Rheumatol. 2023;(75 suppl 9). Available from: https:\/\/acrabstracts.org\/abstract\/efficacy-of-xt-150-a-novel-non-viral-gene-therapy-delivering-il-10v-on-moderate-to-severe-pain-due-to-osteoarthritis-of-the-knee-results-of-a-phase-2-trial\/","journal-title":"Arthritis Rheumatol"},{"key":"e_1_3_5_88_1","unstructured":"ClinicalTrials.gov [Internet]. ClinicalTrials.gov; [cited 2026 May 6]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06704347"},{"key":"e_1_3_5_89_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01780-w"},{"issue":"2","key":"e_1_3_5_90_1","first-page":"C103","article-title":"Impact of intrathecal deliveryof INS1202 AAV9-SOD1-shRNA onhallmarks of neurodegeneration ina murine disease model of ALS andpatient-derivedin vitromodels","volume":"26","author":"Ferraiuolo L","year":"2025","unstructured":"Ferraiuolo L, Thomsen G, Hurley E, et al. Impact of intrathecal deliveryof INS1202 AAV9-SOD1-shRNA onhallmarks of neurodegeneration ina murine disease model of ALS andpatient-derivedin vitromodels. Amyotroph Lateral Scler Frontotemporal Degener. 2025;26(sup2):C103.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"e_1_3_5_91_1","unstructured":"ClinicalTrials.gov [Internet]. ClinicalTrials.gov; [cited 2026 May 6]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07290062"},{"key":"e_1_3_5_92_1","unstructured":"ClinicalTrials.gov [Internet]. ClinicalTrials.gov; cited 2026 May 6]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06100276"},{"key":"e_1_3_5_93_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-013-1125-6"},{"key":"e_1_3_5_94_1","unstructured":"ClinicalTrials.gov [Internet]. ClinicalTrials.gov; [cited 2026 May 6]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06454682"},{"key":"e_1_3_5_95_1","unstructured":"ClinicalTrials.gov [Internet]. ClinicalTrials.gov; [cited 2026 May 6]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06493279"},{"key":"e_1_3_5_96_1","unstructured":"ClinicalTrials.gov [Internet]. ClinicalTrials.gov; cited 2026 May 6]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06849609"},{"key":"e_1_3_5_97_1","unstructured":"VectorY Therapeutics [Internet]. Amsterdam: VectorY Therapeutics; [cited 2026 May 6]. Available from: https:\/\/www.vectorytx.com\/news\/vectory-therapeutics-announces-first-participant-dosed-in-phase-1\/2-pioneer-als-clinical-trial-of-vtx-002-in-people-with-amyotrophic-lateral-sclerosis-als"},{"key":"e_1_3_5_98_1","unstructured":"ClinicalTrials.gov [Internet]. ClinicalTrials.gov; [cited 2026 May 6]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07287397"},{"key":"e_1_3_5_99_1","unstructured":"PackGene [Internet]. Houston (TX): SineuGene Therapeutics; [cited 2026 May 6]. Available from: https:\/\/www.packgene.com\/frontier\/081525-sineugene\/"},{"key":"e_1_3_5_100_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10571-023-01337-5"},{"key":"e_1_3_5_101_1","unstructured":"ClinicalTrials.gov [Internet]. ClinicalTrials.gov; [cited 2026 May 6]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06645197"},{"key":"e_1_3_5_102_1","unstructured":"ClinicalTrials.gov [Internet]. ClinicalTrials.gov; [cited 2026 May 6]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07169175"},{"key":"e_1_3_5_103_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-020-01885-3"},{"key":"e_1_3_5_104_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awad306"},{"key":"e_1_3_5_105_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-020-01607-9"},{"key":"e_1_3_5_106_1","unstructured":"ClinicalTrials.gov [Internet]. ClinicalTrials.gov; [cited 2026 May 6]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05889572"},{"key":"e_1_3_5_107_1","unstructured":"MaaT Pharma [Internet]. Lyon: MaaT Pharma; [cited 2026 May 6]. Available from: https:\/\/www.maatpharma.com\/may-12-2025-maat-pharma-announces-promising-final-data-readout-for-phase-1b-evaluating-maat033-in-amyotrophic-lateral-sclerosis-als\/"},{"key":"e_1_3_5_108_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-75083-z"},{"key":"e_1_3_5_109_1","unstructured":"ClinicalTrials.gov [Internet]. ClinicalTrials.gov; [cited 2026 May 6]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06513546"},{"key":"e_1_3_5_110_1","unstructured":"ClinicalTrials.gov [Internet]. ClinicalTrials.gov; [cited 2026 May 6]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07017946"},{"key":"e_1_3_5_111_1","doi-asserted-by":"publisher","DOI":"10.2174\/1570159X19666210428120514"},{"key":"e_1_3_5_112_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2019.09.020"},{"key":"e_1_3_5_113_1","doi-asserted-by":"publisher","DOI":"10.2174\/1570159X22666231016153606"},{"key":"e_1_3_5_114_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1519513"},{"key":"e_1_3_5_115_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20194666"},{"key":"e_1_3_5_116_1","doi-asserted-by":"publisher","DOI":"10.3390\/nu18050863"},{"key":"e_1_3_5_117_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2017.12.029"},{"key":"e_1_3_5_118_1","doi-asserted-by":"publisher","DOI":"10.2174\/1381612824666180123110042"},{"key":"e_1_3_5_119_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep22827"},{"key":"e_1_3_5_120_1","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcae304"},{"key":"e_1_3_5_121_1","unstructured":"ClinicalTrials.gov [Internet]. ClinicalTrials.gov; [cited 2026 May 6]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03693781"},{"key":"e_1_3_5_122_1","doi-asserted-by":"publisher","DOI":"10.1080\/21678421.2016.1221971"},{"key":"e_1_3_5_123_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2019.05.023"},{"key":"e_1_3_5_124_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-0749-9"},{"key":"e_1_3_5_125_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(25)00173-5"},{"key":"e_1_3_5_126_1","unstructured":"ClinicalTrials.gov [Internet]. ClinicalTrials.gov; [cited 2026 May 6]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05136885"},{"key":"e_1_3_5_127_1","doi-asserted-by":"publisher","DOI":"10.3390\/antiox14010085"},{"key":"e_1_3_5_128_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02253-4"},{"key":"e_1_3_5_129_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2024.155808"},{"key":"e_1_3_5_130_1","doi-asserted-by":"publisher","DOI":"10.1080\/15287394.2025.2470847"},{"key":"e_1_3_5_131_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.27643"},{"key":"e_1_3_5_132_1","unstructured":"GlobeNewswire [Internet]. El Segundo Clene Inc [cited 2026 May 6]. Available from: https:\/\/www.globenewswire.com\/news-release\/2025\/12\/03\/3198843\/0\/en\/Clene-Announces-Statistically-Significant-ALS-Biomarker-Results-Supporting-Accelerated-Approval-Pathway-for-CNM-Au8.html"},{"key":"e_1_3_5_133_1","unstructured":"ClinicalTrials.gov [Internet]. ClinicalTrials.gov; [cited 2026 May 6]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04244630"},{"key":"e_1_3_5_134_1","doi-asserted-by":"publisher","DOI":"10.1002\/jbt.70369"},{"key":"e_1_3_5_135_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.01021"},{"key":"e_1_3_5_136_1","unstructured":"ALS untangled [Internet]. Fort WA: Curcumin; [cited 2026 May 6]. Available from: https:\/\/www.alsuntangled.com\/review\/curcumin\/"},{"key":"e_1_3_5_137_1","unstructured":"ClinicalTrials.gov [Internet]. ClinicalTrials.gov; [cited 2026 May 6]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04654689"},{"key":"e_1_3_5_138_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-018-0606-7"},{"key":"e_1_3_5_139_1","doi-asserted-by":"publisher","DOI":"10.1080\/21678421.2018.1440738"},{"key":"e_1_3_5_140_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16020"},{"key":"e_1_3_5_141_1","unstructured":"MND Association [Internet]. Northampton: TUDCA-ALS; [cited 2026 May 6]. Available from: https:\/\/www.tudca.eu\/top-line-results-announcement\/"},{"key":"e_1_3_5_142_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-11844-6"},{"key":"e_1_3_5_143_1","unstructured":"ClinicalTrials.gov [Internet]. ClinicalTrials.gov; [cited 2026 May 6]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06126315"},{"key":"e_1_3_5_144_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells14080571"},{"key":"e_1_3_5_145_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-025-06785-z"},{"key":"e_1_3_5_146_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30406-X"},{"key":"e_1_3_5_147_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2009.200642"},{"key":"e_1_3_5_148_1","unstructured":"ClinicalTrials.gov [Internet]. ClinicalTrials.gov; [cited 2026 May 6]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT00812851"},{"key":"e_1_3_5_149_1","unstructured":"ClinicalTrials.gov [Internet]. ClinicalTrials.gov; cited 2026 May 6]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03690791"},{"key":"e_1_3_5_150_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15041057"},{"key":"e_1_3_5_151_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12986-025-00902-7"},{"key":"e_1_3_5_152_1","doi-asserted-by":"publisher","DOI":"10.1080\/21678421.2024.2311721"},{"key":"e_1_3_5_153_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnsyn.2020.00034"},{"key":"e_1_3_5_154_1","unstructured":"ClinicalTrials.gov [Internet]. ClinicalTrials.gov; [cited 2026 May 6]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06656702"},{"key":"e_1_3_5_155_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01247-2017"},{"key":"e_1_3_5_156_1","doi-asserted-by":"publisher","DOI":"10.4187\/respcare.02856"},{"key":"e_1_3_5_157_1","unstructured":"ClinicalTrials.gov [Internet]. ClinicalTrials.gov; [cited 2026 May 6]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04391361"},{"key":"e_1_3_5_158_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.56755"},{"key":"e_1_3_5_159_1","unstructured":"ClinicalTrials.gov [Internet]. ClinicalTrials.gov; [cited 2026 May 6]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07047209"},{"key":"e_1_3_5_160_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2025.104513"},{"key":"e_1_3_5_161_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2025.1636303"},{"key":"e_1_3_5_162_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-023-00608-5"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543784.2026.2729512","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/13543784.2026.2729512","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543784.2026.2729512","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:57:15Z","timestamp":1793948235000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543784.2026.2729512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,12]]},"references-count":160,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,3]]}},"alternative-id":["10.1080\/13543784.2026.2729512"],"URL":"https:\/\/doi.org\/10.1080\/13543784.2026.2729512","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,12]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-05-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}